A new Yale study reveals how body temperature affects the immune system's response to the common cold virus. The research, published by the Proceedings of the National Academy of Sciences, may provide additional strategies for developing therapies for colds. In an earlier study, a team of Yale researchers led by Professor of Immunobiology Akiko Iwasaki found that the cold virus replicated more readily when the temperature in the nose dipped below core body temperature (37 degrees C). The researchers determined that at a slightly cooler temperature (33 degrees C), key immune system proteins - interferons - were impaired, allowing the cold virus to reproduce and spread in mouse airway cells.
For the current study, the research team focused on human airway cells, which make little interferons in response to the cold virus, said Iwasaki, who is also an investigator at the Howard Hughes Medical Institute. While examining infected cells incubated at 37 or 33 degrees C, they observed that even in the absence of interferon, cells still controlled the virus, raising the possibility of additional cold-fighting mechanisms.
Further investigation, including mathematical modeling, revealed two additional mechanisms: At core body temperature, infected cells die more rapidly, preventing viral replication. Second, an enzyme that attacks and degrades viral genes, RNAseL, is enhanced at the higher temperature. Each pathway independently contributes to the immune system's defense against the cold virus.
"In this study, we found that there are two additional mechanisms at play," in addition to interferon, Iwasaki said. "All are more optimal at 37 degrees."
The findings underscore the impact of temperature on the immune system's defenses. They also offer further approaches for therapeutically tackling the cold virus, which is a key trigger of asthma. "There are three ways to target this virus now," said Iwasaki.
Other Yale authors are Ellen F. Foxman, James A. Storer, Kiran Vanaja, and Andre Levchenko.
The study was supported by the Howard Hughes Medical Institute, the National Institutes of Health, and the American Asthma Foundation.
Citation: Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1601942113
Source: Yale University
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.